Coronavirus: NAFDAC Approves Mass Production Of Chloroquine

March 21, 2020
202 Views


Despite that disapproval of Chloroquine as the cure of COVID-19, by the Minister of health, Osagie Ehanire, Nigeria’s drug monitoring agency, NAFDAC, has yesterday announced that it has approved the production of Chloroquine for clinical trials in tackling COVID-19.

In a post by Channels TV, the Director-General of the agency, Mojisola Adeyeye, on Friday in Lagos, said NAFDAC is not approving Chloroquine for the treatment of COVID-19 but for clinical trials to find treatment for the virus.

In the case of Chloroquine, it has been demonstrated in the literature and with clinical research which is still ongoing, that Chloroquine is superior to the placebo.

“NAFDAC is not approving Chloroquine as a product that can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.

“Therefore the medicine is being approved just for the clinical trials,” Mr Adeyeye said.

Share this post with your Friends on


Go Back To The Top


Looking for something? Search below



You may be interested

Arokodare: Genk Can Win Belgian Pro League Title
Sports
1 views
Sports
1 views

Arokodare: Genk Can Win Belgian Pro League Title

Webby - November 4, 2024

Tolu Arokodare is optimistic KRC Genk can win the Belgian Pro League title this season, reports Completesports.com.The Smurfs have established…

Man City Suffer Double Injury Setbacks
Sports
2 views
Sports
2 views

Man City Suffer Double Injury Setbacks

Webby - November 2, 2024

Manchester City manager Pep Guardiola has provided an update on the fitness of John Stones and Ruben Dias following Saturday’s…

Former Flying Eagles Star Escapes Major Injury In Belgium
Sports
Sports

Former Flying Eagles Star Escapes Major Injury In Belgium

Webby - November 2, 2024

Nigeria winger Yira Sor is expected to return to action after the international break, reports Completesports.com.Sor sustained an injury in…

Leave a Comment

Your email address will not be published.